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INTRODUCTION 
 
Pleural effusion is one of the common problems in internal 
medicine where diagnosis is easily made in most of the cases. The 
landmark article by Light et al. is the most significant eventin the 
diagnosis of pleural effusion. He classified the pleural effusion into 
transudate and exudate and simplified the diagnostic approach to our 
modern day diagnosis of pleural effusion. In Indian subcontinent 
infectious causes of pleural effusion particularly tuberculosis and 
parapneumonic effusion are still the leading causes of pleural effusion. 
Though the incidence of empyema has come down due to initiation of 
early antibiotic therapy worldwide but in India considerable number of 
empyema and loculated pleural effusion is encountered in tertiary care 
setup. Tuberculosis is the most common cause of effusion in most of the 
case series conducted in India and often diagnosed and treated 
empirically. After the advent of ADA, the diagnosis of tuberculosis has 
become simple and the need for the pleural biopsy is greatly reduced. 
Malignant effusion is often suggested by the hemorrhagic nature of 
effusion, it is common in both primary as well as secondary lung 
malignancy. It produces massive effusion and the diagnostic yield of the 
pleural fluid is low and the diagnosis is easily made without advent of 
biopsy if the pleural fluid aspiration is positive for malignant cells. The 
rare causes of pleural effusion such as rheumatoid effusion, 
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mesothelioma associated effusion, pulmonary embolism associated 
effusion are rarely encountered in our day to day practice. High index of 
suspicion is necessary to diagnosis these rare causes. There is an array of 
newer investigations for diagnosis of effusion in pipeline but none has 
gained wider acceptance among the clinicians. Trials have proven these 
newer investigations are no better than the Light’s criteria. Polymerase 
chain reaction and lysozyme for the diagnosis of tuberculous effusion is 
presently being taken up for study in many centers. Tuberculous antigen 
and antibody is advocated for easier diagnosis and various studies have 
supported their usefulness but needs further validation. C-Reactive 
Protein(CRP) is an early acute phase reactant that is elevated in blood and 
pleural fluid in various inflammatory conditions. CRP measurement will 
be a simple,quick and cost effective for the diagnosis of pleural effusion 
and give a clue to the further workup. Though the measurement of CRP 
has not been advocated by any international guidelines, various studies 
done outside Indian subcontinent has showed positive correlation 
between level of CRP and the type of exudate. This study is undertaken 
to assess the ROLE OF CRP IN THE DIAGNOSIS OF ETIOLOGY OF 
PLEURAL EFFUSION. 
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AIMS AND OBJECTIVES 
AIM: 
To find the role of pleural fluid CRP in etiological diagnosis of 
pleural effusion 
 
OBJECTIVES: 
• To find the diagnostic value of pleural fluid CRP in differentiating 
exudative from transudative effusion. 
 
• To find out the significance of pleural fluid CRP in categorizing 
the cause of exudative pleural effusion into tuberculous effusion, 
parapneumonic effusion, malignant effusion and other. 
 
• To find the place of CRP in diagnostic algorithm of pleural 
effusion. 
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REVIEW OF LITERATURE 
ANATOMY OF THE PLEURA: 
The pleura consist of two membranes: the visceral pleura cover the 
lung surface and the parietal pleura lies outside the visceral pleura. 
Between these two membranes there is a potential space named pleural 
space, which is filled with a thin sheet of fluid, called pleural fluid. The 
main function of the pleural fluid is to eliminate friction forces allowing 
extensive movement of the lung to the chest wall during respiratory  
Movements. 
 
FUNCTIONAL ANATOMY OF PLEURA1: 
Pleura consists of five layers: a) the mesothelium, b)a layer of 
submesothelialconnective tissue, c) a thin layer of elastic tissue d)a 
second layer of connective tissue containing blood and lymph vessels and 
nerves., and e)a fibroelastic layer adherent to the underlying tissue. The 
visceral pleura lack innervation, and its blood supply is more complex 
than the parietal pleura. 
 
BLOOD SUPPLY OF PLEURA:  
Systemic capillaries supply the parietal pleura and acts as principal 
blood supply to parietal pleura. 
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PARIETAL PLEURA BLOOD SUPPLY 
COSTAL PLEURA INTERCOASTAL ARTERY 
MEDIASTINAL PLEURA PERICARDIOPHRENIC 
ARTERY 
DIAPHRAGMATIC PLEURA SUPERIOR PHRENIC AND 
MUSCULOPHRENIC ARTERY 
 
The venous drainage of the parietal pleura is primarily by the 
intercostal veins. Visceral pleura of human beings are thick, and 
nourished by bronchial vessels. 
 
LYMPHATICS OF PLEURA: 
The lymphatic plexus in the costal pleura are mainly confined to 
the intercostal spaces and are absent or minimal over the ribs. The 
lymphatic channels of the pleura covering the costal surface drain 
ventrally towards nodes along the internal thoracic vessels and dorsally 
towards lymph nodes of internal intercostal nodes near the heads of the 
ribs. The lymphatic vessels of the mediastinal pleura pass to the 
tracheobronchial and mediastinal nodes, where as lymphatics of the 
diaphragmatic pleura pass to the parasternal, middle phrenic, and 
posterior mediastinal nodes. 
The visceral pleura3 is abundantly endowed with lymphatic 
vessels3. These lymphatics form a plexus of intercommunicating vessels 
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that run over the surface of the lung toward the hilum and also penetrate 
the lung to join the bronchial lymph vessels by passing through the 
interlobular septa. 
 
INNERVATION OF THE PLEURA: 
Sensory nerve endings are present in the costal and diaphragmatic 
parietal pleura. The intercostal nerves supply the pleura covering the 
costal surface and the outer part of the pleura covering the diaphragm. 
When either of these areas is stimulated, pain is perceived in the adjacent 
chest wall. The central part of the diaphragm is innervated by phrenic 
nerve, and stimulation of diaphragmatic pleura causes the pain to be 
perceived in the ipsilateral shoulder. The visceral pleura is pain 
insensitive due to absence of nerve supply. Therefore, parietal pleura is 
the source of catchy pain and it is due to any disease process that cause 
inflammatory process in the pleura like tuberculous pleurisy. 
 
PLEURAL FLUID: 
In physiological state, pleural fluid is present in between the two 
pleura is very minimal. The mean amount of fluid in the right pleural 
space in normal individuals is 8.4 +4.3 mL. Normally, the quantity of 
fluid in the spaces of each lung is quite similar. Expressed per kg of body 
mass, the total pleural volume in normal, non-smoking humans space is 
0.26 + 0.1mL per kg.  
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PLEURAL FLUID PRESSURE AND DYNAMICS: 
Movement of fluid within pleural membranes is based on the 
balance of hydrostatic and oncotic pressure4between the microvasculature 
and the pleural space. Fluid exchange across the pleural membranes is 
described by Starling’s law7: 
 
FLUID MOVEMENT = L X S {(Pcap-Ppl)} –  (cap-pl) where p 
and  are the hydrostatic and osmotic pressures, respectively, within the 
capillaries (cap) and pleural (pl); L is the hydraulic conductivity of the 
membrane; S is the surface area; and  is the osmotic co-efficient for 
proteins. At the parietal pleura, there is fluid filtration from systemic 
capillaries into the adjacent interstitium and from the latter across the 
mesothelium to pleural space. The actual pleural pressure in humans is 
approximately –5cm H2O at functional residual capacity and –30 cm H2O 
at the total lung capacity. According to this model of pressure gradients, 
net transmembrane starling pressure moves fluid from pleural space to 
visceral pleura and then into pulmonary capillaries.  
Recently, there have been conflicting data concerning the entry and 
exit of pleural fluid normally. Pressure gradients are not the only 
explanation of fluid turnover. The pleural space is analogous to any 
interstitial space, this pressure difference constitutes a gradient for fluid 
movement into, but not out of, the pleural cavity. The normal protein 
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concentration in the pleural fluid is low, which implies sieving of the 
proteins across a high-pressure gradient such as from the high-pressure 
systemic vessels5. Lymphatic drainage via the lymphatic stomas of the 
parietal pleura, solute-coupled liquid absorption on both parietal and 
visceral, contributes additionally to the exit of fluid from the pleural 
cavity. 
 
MECHANISM OF PLEURAL EFFUSION: 
 INCREASED PLEURAL FLUID FORMATION: 
 
INCREASED INTERTITIAL FLUID IN THE LUNG: 
• LEFT VENTRICULAR FAILURE 
• PNEUMONIA 
• PULMONARY EMBOLUS 
 
INCREASED INTRAVASCULAR PRESSURE IN PLEURA: 
• RIGHT OR LEFT VENTRICULAR FAILURE 
• SUPERIOR VENA CAVAL SYNDROME 
 
INCREASED PERMEABILITY OF THE CAPILLARIES IN 
PLEURA: 
• PLEURAL INFLAMMATION 
• INCREASED LEVEL OF VASCULAR ENDOTHELIAL FACTOR 
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INCREASED LEVEL OF PLEURAL FLUID PROTEIN: 
DECREASED PLEURAL PRESSURE: 
• LUNG ATELECTASIS OR INCREASED ELASTIC RECOIL OF  
      THE LUNG 
 
INCREASED FLUID IN PERITONEAL CAVITY 
• ASCITES OR PERITONEAL DIALYSIS 
 
DISTRUPTION OF THORACIC DUCT 
DISRUPTION OF BLOOD VESSELS IN THE THORAX 
 DECREASED PLEURAL FLUID ABSORPTION: 
• OBSTRUCTION OF THE LYMPHATICS DRAINING THE        
           PARIETAL PLEURA 
• ELEVATION OF SYSTEMIC VASCULAR PRESSURE 
• DISRUPTION OF THE AQUAPORIN SYSTEM IN THE  
          PLEURA 
 
CAUSES OF PLEURAL EFFUSION: 
TRANSUDATIVE CAUSES OF PLEURAL EFFUSIONS ARE 
1. CONGESTIVE HEART FAILURE 
2. HEPATIC HYDROTHORAX 
3. NEPHROTIC SYNDROME 
4. PERITONEAL DIALYSIS 
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5. FONTAN OPERATION 
6. URINOTHORAX 
7. SUPERIOR VENACAVAL SYNDROME 
8. ATELECTASIS 
9. MISPLACED CENTRAL LINE 
10. PERICARDIAL DISEASE 
11. PULMONARY EMBOLI 
12. SARCOIDOSIS 
13. AMYLOIDOSIS 
14. CEREBROSPINAL FLUID LEAK INTO THE PLEURA 
 
EXUDATIVE CAUSES OF PLEURAL EFFUSION: 
1. MALIGNANCY: 
(Mesothelioma, lymphoma of body cavity, metastasis to lung and  
pleura, lymphoma associated with pyothorax) 
2. INFECTION: 
(TB, bacterial pneumonia, invasive fungal disease, viral infections,  
 parasitic disease) 
3. PULMONARY EMBOLIZATION 
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4. ABDOMINAL CAUSES 
(Oesophageal perforation, acute and chronic pancreatitis, 
abdominal abscesses, diaphragmatic hernia, post abdominal 
surgery, varicealsclerotherapy, post hepatic transplant) 
5. COLLAGEN VASCULAR DISORDERS 
(Rheumatoid pleuritis, Systemic lupus erythematosus, Wegeners 
granulomatosus, Churg-Strauss syndrome) 
6. POST CORONARY ARTERY BYPASS GRAFT OPERATION 
7. EXPOSURE TO ASBESTOS. 
8. SARCOID LUNG 
9. UREMIC PLEURITIS AND EFFUSION 
10. MEIGS SYNDROME 
11. YELLOW NAIL SYNDROME 
12. DRUG CAUSING PLEURAL EFFUSION. 
a. Nitrofurantoin 
b. Clozapine 
c. Methotrexate 
d. Interleukin  
e. Dandrolene 
f. Methysergide 
g. Bromocriptine 
h. Procarbazine 
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i. Amiodarone 
j. Dasatinib 
13. TRAPPED LUNG SYNDROME. 
14. RADIATION EXPOSURE 
15. AFTER CARDIAC SURGERY 
16. HEMOTHORAX 
17. IATROGENIC INJURY 
18. OVARIAN HYPERSTIMULATION SYNDROME 
19. DISEASES OF PERICARDIUM 
20. CHYLOTHORAX 
 
SYMPTOMS OF PLEURAL EFFUSION: 
The symptoms of pleural effusion are per se due to effusion rather 
than due to underlying etiology. 
PLEURITIC CHEST PAIN 
DULL ACHING CHEST PAIN 
DRY NON PRODUCTIVE COUGH  
DYSPNEA 
 
Some of the patients with pleural effusion do not have catchy pain 
instead have dull aching chest pain that may suggest underlying pleural 
malignancy. Very rarely pleuritic pain resulting from pleural 
inflammation radiates to abdomen due to the intercostal nerves that 
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supply the parietal pleura. Pain may also radiate to the tip of the shoulder 
when the diaphragm is involved. The reason behind the dry cough 
production by pleural effusion is probably due to the compression of the 
pleural fluid resulting in contact of the opposing bronchial walls resulting 
in cough. Pleural effusion reduces the lung volume and result in 
breathlessness. 
 
PHYSICAL EXAMINATION: 
The physical examination findings of pleural effusion is deviation 
of trachea to opposite side, shifting of apical impulse, intercostal fullness, 
diminished expansion of chest on the affected side, stony dull on 
percussion and diminished breathsounds and decreased vocal resonance. 
The presence of tenderness in the intercostal area indicates empyema and 
occasionally there will be pus pointing and it is called as empyema 
necessitans.  
 
CLASSIFICATION OF PLEURAL FLUID INTO TRANSUDATE 
AND EXUDATE: 
It is imperative to classify the pleural effusion into exudate and 
transudate. In the past before the Lights classification6 was used pleural 
fluid protein was alone used to classify the pleural effusion. About 10% 
of pleural effusion was misclassified by this method and led to the 
introduction of Light’s criteria. Light’s criteria proved 99% of accuracy 
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in separating exudate and transudate led to the Light’s criteria as the 
standard rule.  
 
LIGHT’S CRITERIA: 
1) Pleural fluid protein divided by serum protein greater than 0.5 
2) Pleural fluid LDH divided by serum LDH greater than 0.6 
3) Pleural fluid LDH more than 2/3rd of the upper limit of normal  
 serum LDH. 
For the effusion to be classified as exudate atleast one of the 
criteria should be met. Transudate should not meet any of the criteria. 
There are numerous tests in voyage for classification of the pleural 
effusion like pleural fluid cholesterol, pleural fluid-serum albumin ratio, 
soluble leukocyte selectin, cytokines, uric acid, and pleural fluid to serum 
cholinesterase. 
 
IMAGING OF PLEURAL EFFUSION: 
Diseases of the pleural space8 can be made out with ease by a 
various radiographic methods using frontal, lateral, oblique and decubitus 
skiagrams. Pleural effusions accumulate in the most dependent part of the 
pleural cavity, because lung which is relatively less dense than the 
surrounding pleural fluid, floats in the effusion. Because of the downward 
pull due to gravity the initial accumulation of fluid occurs in a 
subpulmonic location, ie between the inferior surface of the lower lobes 
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and diaphragm.75 % of fluid occupies the subpulmonic space without 
moving into other pleural recess.As it accumulates pleural liquid spills 
over into the costophrenic sulcus posteriorly, anteriorly and then 
laterally.The amount of effusion can be calculated based on standard 
posterior-anterior and lateral view of standard chestX ray. Minimum of 
75 mL is needed to obliterate the posterior costophrenic sulcus, and a 
minimum of 175 mL is necessary obscure the lateral costophrenic sulcus 
on the upright chest X- ray. 500 mL is necessaryto obliterate the 
diaphragmatic contour on an erect chest X ray; if pleural effusion reaches 
the level of the fourth rib, close to 1000 mL are present in the pleural 
space.  
Chest ultrasound can detect as little as 5-50 ml of pleural fluid. 
Ultrasound is useful in small and loculated effusions. Ultrasound also 
detects tumors associated with pleura and very useful in in diagnosing 
effusions in recumbent patients like patients on mechanical ventilation. 
When septations are present ultrasound detects better than CT scan. 
Parietal pleural thickening, visceral pleural thickening diaphragmatic 
thickening diaphragmatic nodules has good sensitivity and specificity for 
diagnosis of malignant effusions. 
CT thorax detects very small effusions. In the presence of 
inflammation CT can clearly identify thickening of the visceral and 
parietal pleura and their enhancement after the contrast injection. CT also 
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helps to visualize the lung parenchyma. A pleural effusion appears on CT 
as a dependent sickle-shaped opacity with a lower CT number than that 
of any adjacent pleural thickening or mass. Loculated pleural effusions 
have lenticular configuration with smooth margins and they displace the 
adjacent parenchyma. 
 
CAUSE OF BILATERAL EFFUSION:(Rabin et al) 
1. CONGESTIVE HEART FAILURE 
2. VIRAL INFECTIONS CAUSING SEROSITIS, eg. DENGUE 
3. RHEUMATOLOGICAL DISEASES  
          eg. SLE AND RHEUMATOID ARTHRITIS 
4. MALIGNANCY 
5. CONTARINI’S SYNDROME. 
6. PULMONARY EMBOLISM 
7. NEPHRITIS 
8. AMYLOIDOSIS 
9. CIRRHOSIS 
10. EOSINOPHILIC PNEUMONIA 
11. CONSTRICTIVE PERICARDITIS. 
 
RIGHT SIDED PLEURAL EFFUSION: 
1. CONGESTIVE HEART FAILURE 
2. HEPATIC HYDROTHORAX 
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3. SUBDIAPHRAGMATIC ABSCESS 
4. LIVER ABSCESS RUPTURE 
 
LEFT SIDED EFFUSION: 
1. PANCREATITIS. 
2. DRESSLERS SYNDROME. 
3. LEFT SUBDIAPHRAGMATIC ABSCESS. 
4. ESOPHAGEAL RUPTURE. 
 
MASSIVE EFFUSION9: 
Massive effusion is defined as effusion occupying upto second 
intercostal space. The other definition is the effusion occupying the entire 
hemithorax is called massive.  
 
CAUSES: 
1. MALIGNANCY. 
2. PARAPNEUMONIC EFFUSION. 
3. TUBERCULOSIS 
4. TRANSUDATIVE EFFUSION. 
 
THORACENTESIS: 
Thoracocentesis is a principal diagnostic procedure in a patient 
with pleural effusion. Analysis of the pleural fluid will help us to 
categorize as either transudate or exudate. Thoracocentesis, as a 
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therapeutic procedure, may help to decrease respiratory distress in 
patients with massive effusions. There is insufficient data on the safety of 
this procedure in patients who are using anticoagulants or decreased 
platelet count. It should be performed with great caution in patients who 
are on ventilators because of increased risk of tension pneumothorax. 
 
COMPLICATIONS OF THORACENTESIS: 
1. Pneumothorax 
2. Kidney or Lung puncture 
3. Hemothorax 
APPROACH TO DIAGNOSIS OF PLEURAL EFFUSION: 
GROSS APPEARANCE, ODOR, AND CHARACTER OF 
PLEURAL FLUID: 
The transudate effusion on gross appearance is mostly clear fluid 
and straw coloured. Exudate tends to be more amber like and appears 
cloudy, if the total count in the fluid is high. A fresh drawn exudate clots 
on prolonged standing, while an older one has less fibrin content and, 
remains in a fluid state. Bloody effusionis due to damage to a vessel 
during thoracocentesis and by pleural or lung biopsy. If the fluid is 
uniformly red, or brown colour, it indicates presence of malignancy in 
most cases, although tuberculosis, leukemia, infarction and rheumatoid 
pleuritis may also cause haemorrhagic effusion.chyle, appears like milk, 
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though chronic effusions of any cause can mimic chyle and it is called 
pseudochyle. It is due to presence of globules of fat formed from dying 
cells. Purulent fluid in cases of frank empyema is easily recognized. 
Ammonia odor indicates urinothorax. Putrid odor indicates anaerobic 
empyema. 
COLOR SUGGESTED DIAGNOSIS 
STRAW 
TRANSUDATE, PAUCICELLULAR 
EXUDATE 
RED HEMOTHORAX,MALIGNANCY,OTHERS 
WHITE (MILKY) CHYLOTHORAX OR, PSEUDOCHYLE 
YELLOWISH GREEN RHEUMATOID ARTHRITIS 
BILE 
CHOLOTHORAX-BILIOPLEURAL 
FISTULA 
BROWN 
OLD HAEMORRHAGIC EFFUSION, 
RUPTURE OF AMOEBIC LIVER 
ABSCESS. 
BLACK ASPERGILLUS NIGER SPORES 
 
 
 
 
 
20 
 
CHARACTER OF PLEURAL EFFUSION: 
ANCHOVY SAUCE RUPTURE OF AMOEBIC LIVER ABSCESS  
FOOD PARTICLES RUPTURE OF OESOPHAGUS 
VISCOUS PLEURAL EFFUSION IN MESOTHELIOMA 
SATIN LIKE 
SHEEN 
CHOLESTEROL EFFUSION 
DEBRIS RHEUMATOID EFFUSION 
PUS EMPYEMA 
 
DISEASES COMMENT 
TUBERCULOSIS COMMONEST CAUSE.LYMPHOCYTE - 90-95% 
LYMPHOMA ALL CELLS WHICH HAS NUCLEI ARE 
LYMPHOCYTES 
RHEUMATOID 
PLEURISY 
SOMETIMES ASSOCIATED WITH 
UNEXPANDED LUNG 
CHYLOTHORAX COMMONEST CAUSE-LYMPHOMA. 
SARCOIDOSIS LYMPHOCYTES >90% 
POST CORONARY 
ARTERY  BYPASS 
GRAFT 
OCCURS AFTER 2 months FOLLOWING 
SURGERY 
YELLOW NAIL 
SYNDROME 
CHARACTERISTICALLY A DISCORDANT 
EXUDATE. 
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PLEURAL FLUID  pH: 
The pleural fluid pH is considered low if pH value is less than 7.30 
with a blood pH in normal range. Most transudate has pH ranging from 
7.45 to 7.55. pH of most exudate effusion will be in the range of 7.30-
7.45. In parapneumonic effusion and esophageal rupture the acidic pH is 
due to rapid rate of glucose usage and accumulation of end products of 
metabolism. 
In malignancy and rheumatoid pleural effusion abnormally 
thickened pleura prevents diffusion of glucose into the pleural space and 
back diffusion of carbon dioxide resulting in decreased pH. 
 
PLEURAL FLUID GLUCOSE: 
In normal state glucose concentration in the blood and pleural 
space is equal due to free diffusion of glucose26. Pleural fluid glucose<60 
mg/dLis present in almost always due to one of the four disorders, 
namely TB effusion, parapneumonic effusion, pleural tumors, or 
rheumatoid disease.Rarely pleural effusion with glucose <60mg/dL is 
found include paragonimiasis infection, hemothorax, Churg-Strauss 
syndrome and, lupus pleuritis. The lower the pleural fluid glucose, the 
more likely that one is dealing with a complicated parapneumonic 
effusion. In rheumatoid pleurisy glucose is less than 30 mg/dL in 75% of 
patients. Low glucose in empyema and parapneumonic effusion is 
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associated with bad prognosis and indication for intercostal drainage tube 
insertion. 
 
PLEURAL FLUID PROTEIN AND LDH: 
The total protein may be helpful in diagnosing pleural effusion. 
Tubercular effusion almost always has protein concentration more than 4 
g/dL, while parapneumonic, malignant effusion have a wide range of 
total protein level.when total protein level10 is more than 
7g/dLWaldenstromsmacroglobulinemia and multiple myeloma should be 
considered. Several features about the pleural fluid LDH may also help in 
the diagnostic evaluation of a pleural effusion. With a discordant exudate 
(an exudate by protein but not LDH criterion), the differential should 
include malignancy, resolving parapneumonic effusion, sarcoidosis, 
chylothorax, yellow nail syndrome, and a hypothyroidism. When an 
exudate is discordant by LDH only, malignancy, parapneumonic effusion 
and pneumocystis carinii pneumonia should be considered. Considering 
the upper end of the serum LDH of 200 IU/l, pleural fluid LDH 
concentration of >1000 IU/L is found in one of the following disorders 
complicated parapneumonic effusion or emphyema, rheumatoid pleurisy, 
or pleural paragonimiasis. AnLDH of > 1000 IU/L in pleural fluid is 
rarely observed with malignancy and with a tuberculous pleural effusion. 
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PLEURAL FLUID CYTOLOGY19: 
 Increased neutrophil15 count in the pleural fluid isdue to interleukin 
8, which is the major chemotaxin for neutrophils. The causes of increased 
polymorphs are parapneumonic effusions, tuberculosis in early stages. 
 The causes of increased lymphocyte count in the pleural fluid are 
tuberculosis and malignancy, 
 
PLEURAL FLUID EOSINOPHILIA20: 
Eosinophilia in pleural fluid is defined as a eosinophil count in 
pleural fluidmore than 9% of the total cells. Interleukin-5 is the vital 
chemotactic factor attracting eosinophils from bone marrow into the 
pleural cavity. Pneumothorax is one of the common causes of pleural 
fluid esinophilia. Other causes include hemothorax, benign asbestos 
pleural effusion, pulmonary embolism, postthoracentesis, parasitic 
disease, fungal disease, drug induce, lymphoma, carcinoma, Churg-
Strauss syndrome. 
 
MESOTHELIAL CELLS: 
Pleural cavity is lined by mesothelial cells2. They are present in 
small amount in normal pleural fluid. Size of mesothelial cells is usually 
12 to 30 micrometer in diameter. Mesothelial cells are uncommon in 
tuberculous pleural effusion. But patients with AIDS may have increased 
amount of mesothelial cells when they develop tuberculous pleural 
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effusion. The absence of mesothelial cells is common with complicated 
parapneumonic effusion. 
 
PLEURAL FLUID AMYLASE: 
The finding of an amylase rich pleural effusion, defined as a 
increased amylase in pleural fluidmore than upper limit of normal for 
serum amylase or a pleural fluid-serum amylase ratio more than 1 
signifies that the exudative effusion is either due to pancreatic disease, 
malignancy, esophageal rupture. Pleural fluid amylase may be normal 
initially in acute pancreatitis but increases as the disease progresses. In 
chronic pancreatitis amylase is always elevated and may reach very high 
level, often >100,000 IU/L. Serum amylase may be elevated due to 
diffusion from the pleural space back into the blood or may be normal. 
Approximately 10-14% of patients with a malignant pleural effusion, 
present with an increased pleural fluid amylase concentration. Isoenzyme 
analysis of these amylase rich effusion demonstrate that most of the 
amylase is of salivary type. The most common malignancy causing a 
salivary amylase rich pleural effusion is adenocarcinoma of lung with 
adenocarcinoma of ovary being the next frequent cause. Hematological 
malignancies are also associated with salivary type amylase in pleural 
fluid. 
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PLEURAL FLUID ADA: 
Adenosine deaminase, an enzyme important in the degradation of   
purine and required for lymphocyte differentiation and is involved in 
maturation of monocyte-macrophage lineage. ADA level is higher in 
tubercular effusions than other exudativepleural effusion. In general, a 
cutoff level between 40 and 45 U/L is used with levels above indicating 
tuberculous pleural effusion. The sensitivity and specificity of pleural 
fluid ADA level in the diagnosis of tuberculous pleural effusion is more 
than 90%. The level of ADA in patients with and without AIDS is 
comparable and renal transplant patients who develop a tuberculous 
pleural effusion have an elevated pleural fluid ADA level. Other 
important causes of increased ADA level are empyema and effusion in 
rheumatoid arthritis. Rare causes of higher pleural fluid ADA levels are 
minor percent of other neoplasms, patients with Q fever and with 
brucellosis. The isoenzymes of ADA are ADA1 and ADA2. ADA1 is 
ubiquitous and is produced by lymphocytes, neutrophils, monocytes, and 
macrophages. In contrast, ADA2 exists only in monocytes and 
macrophages. The increase in activity of ADA is mainly due to ADA2. In 
routine practice, ADA isoenzymes measurementis not needed to 
ascertainthe diagnosis of tuberculous effusion. However, in certain 
instances they can be quite useful. 
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INTERFERON –GAMMA: 
Interferon –gamma is produced by the CD4 + T lymphocytes that 
migrate into pleural cavity in tuberculosis. Interferon-gamma appears to 
be a useful defence mechanism. Interferon-gamma enhances 
polymyristate acetate-induced hydrogen peroxide production in 
macrophages, facilitating elimination of intracellular parasites. This 
lymphokine also inhibits mycobacterial growth in human monocytes. 
Interferon gamma >140pg/ml is significant for tubercular pleural 
effusion. 
 
LIPID ANALYSIS: 
Analysis of pleural fluid triglyceride is vital to the diagnosis of a 
suspected chylothorax. Pleural fluid level of triglyceride more than 
110mg/dL strongly supports the diagnosis. In about 15% of patients  with 
triglyceride concentration < 110 mg/dL and 3% have values less than 
50mg/dL.If there is strong suspicion of chylothorax in these patients 
lipoprotein electrophoresis of the pleural fluid should be done. The 
cholesterol level in a chylothorax is generally less than 200mg/dL. Fat 
globules may be noted on sudanIII staining which stains chylomicrons 
orange. 
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N- TERMINAL PRO-BNP: 
Measurement of N-terminal pro-brain natriuretic peptide10,11in 
serum or blood should be considered in cases of effusion in the setting of 
congestive heart failure if the cause of effusion is in doubt. When the 
ventricles are subjected to increased pressure or volume, BNP is released. 
The biologically active BNP and the larger N-terminal-pro-brain 
natriuretic peptide are released into circulation. The threshold for the 
diagnosis of heart failure recommended is 1500pg/mL of pro-BNP. 
 
TUMOR MARKERS IN PLEURAL FLUID: 
No single pleural fluid tumor marker is accurate enough for routine 
use in the diagnostic evaluation of pleural effusion. CEA, CA-125,CA-
15-3 and cytokeratin 19 fragments, but clinical usefulness is limited. 
Mesothelin is a newer tumor marker for malignant mesothelioma that is 
present increased in both effusion and serum. Soluble mesothelin-related 
peptides are believed to be either cleaved peptide fragments of 
mesothelin, or abnormal variants of mesothelin that are unable to bind to 
membranes and are found in the serum. Mesothelin has got a sensitivity 
range of 48-84% and specificity range 70-100% for diagnosis of 
mesothelioma. Adenocarcinoma of lung, lymphoma, ca ovary, metastatic 
pancreatic carcinoma also have positive results.  
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PLEURAL BIOPSY: 
Pleural biopsy typically follows CT scan in undiagnosed pleural 
effusion. There are two common types of biopsy used. One is closed 
pleural biopsy and cutting needle biopsy done with the help of CT scan 
called as guided biopsy. When tuberculosis is suspected closed pleural 
biopsy using ultrasound guidance is preferred. When pleural-based mass 
is visible CT guided biopsy is needed. Thoracoscopic pleural biopsy is 
increasingly used to diagnose malignancy when an obvious mass is not 
visible on CT, when percutaneous biopsy is negative or when patchy 
disease is suspected. Open pleural biopsy is rarely used nowadays. 
CLOSED PLEURAL BIOPSY: 
Abrams needle or Cope needle is used to for performing closed 
pleural biopsy. It is operator dependent. It is most useful to diagnose 
diseases such as tuberculous pleural disease and rheumatoid pleuritis. It is 
also useful tool in undiagnosed case of lymphocytic effusion. 
Pneumothorax is an established complication of this procedure. 
CT guided cutting needle biopsy: 
It is used to get biopsy of pleural based mass and pleural biopsy in 
cytology negative malignant effusion. Incidence of pneumothorax is 
lesser when compared to closed pleural biopsy. 
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ELECTRON MICROSCOPIC EXAMINATION: 
The diagnosis of mesothelioma and metastatic carcinoma to the 
pleural is made in most instances by cytology and immunohistochemical 
assessment, but electron microscopy still plays a decisive role in cases 
with unusual morphology or anomalous histochemical reactions. The 
ultrastructural features of mesothelioma are so characteristic as to be 
almost diagnostic. These characteristics include characteristic microvilli; 
the absence of microvillus core rootlets, glycocalyceal bodies, and 
secretory granules; the presence of intracellular desmosomes, junctional 
complexes, and intracytoplasmiclumina, and characteristic microvilli. 
The appearance of the microvilli is the most important diagnostic feature. 
 
HYALURONIC ACID: 
Pleural fluid from patients with mesothelioma is abnormally viscid. 
The increased viscosity in such fluids is due to the presence of increased 
hyaluronic acid. The measurement of hyaluronic acid is yet to be 
validated. 
 
LECTIN BINDING: 
Lectins are a class of glycoproteins of non-immune origin that bind 
specifically bind to carbohydrate groups found ubiquitously in various 
biologics products. Kawai et al investigated lectin biding in 23 pleural 
mesotheliomas, 6 effusions with reactive mesothelial cells, and 28 well 
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differentiated pulmonary adenocarcinomas and found significant.At - 
present time, such studies should be considered experimental. 
 
LYSOZYME: 
Lysozyme is a low molecular weight protein with bacteriolytic 
property. The level of lysozyme in the pleural fluid tends to be elevated 
in the patients with tuberculous pleural effusion,when compared to other 
exudates. Lysozyme levels in tuberculous pleural effusions are greater 
than those in malignant pleural effusions. The role of lyzozymes in 
diagnosing pleural effusion needs further study to confirm its role. Recent 
studies have suggested positive role of this enzyme in evaluation of 
effusion 
 
DISCRIMINATION BETWEEN EXUDATIVE AND 
TRANSUDATIVE PLEURAL EFFUSION: EVALUATING 
DIAGNOSTIC TESTS IN THE PLEURAL SPACE: 
The etiologies of many effusions12 remain uncertain after routine 
pleural fluid analysis. For such patients, classification of pleural fluid into 
transudate and exudate allows the clinicians to simplify their differential 
diagnosis and pursue the more likely diagnosis with further testing. It 
should be emphasized, however, that classification of an effusion as an 
exudate or transudate for any individual patient by existing techniques 
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represents an inexact, probabilistic statement of what conditions are more 
likely than others as potential etiologies of an effusion.  
Exudative effusion is defined by the presence of high 
concentrations of relatively large molecular weight compound. Pleural 
fluid protein and LDH arethe two large molecular weight compound. 
Light’s rule is the most commonly used strategy and include three criteria 
(1) A pleural fluid LDH of more than 67% of the upper limit of normal 
for the laboratory’s serum value, (2) a pleural fluid-to-serum LDH ratio 
>0.6 (3) a pleural fluid-to-serum protein ration >0.5. These criteria are 
used in an “or” rule wherein a positive result for any one criterion defines 
exudate. Many clinical studies found that Light’s rule has a sensitivity of 
95% to 97%, a specificity of 65% to 80% and an overall diagnosis 
accuracy of 88% to 93% for identifying exudates. Because of its high 
sensitivity, Light’s rule performs well as a screening test for identifying 
nearly all exudate. Despite the high sensitivity, the identification of a 
transudative effusion by Light’s criteria does not exclude the possibility 
of a malignant etiology considering that 5% of malignant pleural effusion 
present with transudates by Light’s rule. Due to its only moderate 
specificity, however, Light’s rule misclassifies as exudates in 15 to 30% 
of transudative effusion. This misclassification exposes some patients 
with true transudates to potential risks of unnecessary diagnostic studies 
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if clinicians over rely on the results of Light’s rule with out considering a 
patients entire clinical picture. 
Another limitation of Light’s rule13relates to its two criteria that are 
mathematically coupled and consequently, do not function well when 
combined diagnostic rule due to multicollinearity effects. Both the 
criteria “pleural fluid LDH” and “pleural fluid-to-serum LDH ratio” 
contain the same biochemical feature, that is, LDH concentrations. 
Heffner and coworkers proposed an “Abbreviated Light’s rule” 
that removes the LDH ratio criterion and thereby simplifies Light’s rule 
that yet maintains a high overall diagnostic accuracy equivalent to the 
three-criteria rule. The high diagnostic accuracy of the Abbreviated 
Light’s rule as compared with the full three-criteria was recently 
confirmed. 
The importance of accurate classification14 of pleural effusions and 
the moderate specificity of Light’s rule have stimulated many 
investigators to evaluate other pleural fluid tests and diagnostic rules and 
compare their performance with Light’s rule. Examined tests include 
pleural fluid –to-serum albumin ratio, pleural fluid cholesterol, pleural 
fluid-to-serum cholesterol ratio, pleural fluid-to-serum bilirubin ratio, 
pleural fluid-to-serum cholinesterase ratios, cell free DNA and a host of 
other tests that include aspartate transaminase, interleukin-1 beta, uric 
acid, C-reactive protein, alanine transaminase, alkaline phosphatase, 
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creatinine kinase, ferritin, interleukin-8, tumor necrosis factor-alpha and 
gamma-glutamyltransferase to name a few. The cutoff points established 
for the most commonly proposed tests table  
TEST REPORTED  
CUTOFF POINTS 
Pleural fluid protein >3 
Pleural fluid cholesterol 54mg/dL 
Pleural fluid to serum cholesterol ratio >0.3 
Albumin gradient <1.2 
Pleural fluid to serum bilirubin ratio >0.6 
 
EXUDATIVE PLEURAL EFFUSION: 
TUBERCULOUS PLEURAL EFFUSION: 
Pleural effusion is the second most common22 form of 
extrapulmonary tuberculosis after lymphatic involvement. The tubercular 
pleural effusions are thought to result from a delayed hypersensitivity 
reaction to mycobacteria and mycobacterial antigens in the pleural space. 
The organism and /or their antigens probably enter the pleural space due 
to leakage of a sub-pleural focus. They can manifest as primary disease or 
reactivated tuberculosis. Isolated pleural effusion usually reflects recent 
primary infection, and collection of fluid in the pleural space represents a 
hypersensitivity reaction resulting in increased capillary permeability and 
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subsequent derangement in lymphatic clearance of proteins and fluid 
from pleural cavity because of occlusion of pleural stoma. But in 
reactivated disease often lesions in lung are present. 
MALIGNANT PLEURAL EFFUSION18: 
A malignant pleural effusion is diagnosed by detecting exfoliated 
malignant cells in pleural fluid or demonstrating these cells in pleural 
tissue obtained by percutaneous pleural biopsy, thoracoscopy, or 
thoracotomy.In number of patients even though the pleural effusion is 
caused by malignancy, neoplastic cells cannot be demonstrated in pleural 
fluid or pleural tissue and, in fact probably are not present in these tissue. 
These are called as paramalignanteffusions23. Lymphatic obstruction 
appears to be most common mechanism for the development of a 
paramalignant effusion, for the accumulation of large volumes of fluid. 
Other local effects of the tumorcausing a paramalignant effusion are 
bronchial obstruction resulting in pneumonia or atelectasis.lymphatics are 
situated beneath the parietal pleura over the intercostal spaces. An 
important feature of the parietal pleura is lymphatic stoma, 2- to 12- 
micrometer openings between parietal pleural mesothelial cells. 
Involvement of lymphatics play a major role in development of effusion. 
The common tumor31 producing effusion is lung, breast, lymphoma, 
ovary, stomach, unknown primary. 
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The treatment modalities available for malignant effusions are 
1) Observation 
2) Therapeuticthoracentesis 
3) Chest catheter drainage only 
4) Chest catheter drainage with chemical pleurodesis 
5) Thoracoscopy with talc insufflation 
6) Long term indwelling pleural catheter 
7) Pleural abrasion 
8) Chemotherapy 
9) Radiotherapy 
 
PARAPNEUMONIC EFFUSION: 
A parapneumonic effusion is any pleural effusion associated with 
bacterial pneumonia or lung abscess25.Parapneumonic effusions are 
usually small, but if depth of the effusion is greater than 10mm on the 
decubitus chest radiograph, a diagnostic thoracentesis should be done. 
Pleural effusions secondary to pneumonia arise from an inflammatory 
process contiguous to the visceral pleura27.The effusion derives from the 
fluid entering the lung interstices, transversing the visceral pleura, and 
accumulates in the pleural space when the rate of accrual exceeds the 
capacity of the parietal pleural lymphaticsto remove the fluid. The fluid is 
classically as an exudate satisfying the Light’s criteria. Parapneumonic 
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effusion occurs in 50% of streptococcus pneumonia but the organism can 
be demonstrated in fewer than 5% of patients. In contrast, culture of the 
pleural fluid is positive in 20% of adults and 80% of children with pleural 
effusion secondary to staphylococcus aureus infection. Pleural effusion 
also develop in 40 to 50% of gram negative aerobic pneumonias, and 
majority of these are culture positive pseudomonas species and 
Escherichia coli account for more than two thirds of all infections of 
pleural space caused by aerobic gram-negative organisms. Pleural 
effusions occur in 30-50% of patients with pneumonia due to legionella 
species. Complicated parapneumonic effusion requires tube 
thoracostomy. The indications for tube thoracostomy are pleural fluid 
loculations, effusion filling more than half of the hemithorax, air-fluid 
level, pus in the pleural space, positive stain for microorganisms, positive 
pleural fluid culture, pleural fluid pH<7.2, pleural fluid glucose 
<60mg/dl. Empyema is defined by the presence of pus in the pleural 
space. Direct extension of a pulmonary parenchymal infection into the 
pleural space causes empyema. Anaerobic infections cause foul smelling 
empyema. Tuberculosis can also cause empyema. 
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RHEUMATOID ARTHRITIS AND SYSTEMIC LUPUS 
ERYTHEMATOSUS: 
Pleural disease is the most common intrathoracic manifestation of 
rheumatoid arthritis16. It usually affects middle-aged men and is 
characterized by a low pleural fluid glucose level. Thickening of visceral 
and parietal pleura is prominent in rheumatoid pleural effusion. The most 
consistent finding is the replacement of the normal mesothelial cell 
covering by a pseudo-stratified layer of epithelial cells with focal 
multinucleated giant cells, regular papillae containing branched 
capillaries, and occasional cholesterol clefts. Most patients are 
asymptomatic, but breathlessness may result from pulmonary 
compression in large effusions. Rheumatoid effusions are associated with 
nodules in 50% of patients and many patients have severe disease. 
In SLE17, pleural effusions appear up to 40% of patients. Even 
more,many patients may present with pleuritic chest pain without 
effusion. The pleural effusions are small in volume and bilateral in 50% 
of patients. 
 
PULMONARY EMBOLISM: 
The diagnosis most commonly overlooked in the differential 
diagnosis of a patient with an undiagnosed pleural effusion21 is 
pulmonary embolism. At least 30% of patients with pulmonary embolism 
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have an associated pleural effusion. The pleural effusion may be 
unilateral or bilateral. The effusion is almost always exudate. The pleural 
red blood cell counts exceeds 100,000/l in fewer than 20% and is below 
10,000/l in at-least 30%. 
 
RARE CAUSES OF PLEURAL EFFUSION: 
PARASITIC CAUSE OF PLEURAL EFFUSION: 
PARASITIC CAUSES: 
AMEBIASIS 
HYDATID DISEASE 
PARAGONIMIASIS 
PNEUMOCYSTIS CARINI 
 
AMEBIAIS: 
Pleural effusion occurs by two mechanisms 
1) Sympathetic effusion37 due to irritation of diaphragm. 
2) Rupture of liver abscess  
About 20 to 30% of patients have exudative sympathetic effusion. 
And the effusion is usually mild to moderate in quantity. Pain referring to 
shoulder gives a clue to the underlying liver process.  
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FUNGAL INFECTIONS: 
ASPERGILLOSIS 
BLASTOMYCOSIS 
COCCIDIOIDOMYCOSIS 
CRYPTOCOCCOSIS 
HISTOPLASMOSIS 
CANDIDIASIS 
 
 
ASPERGILLOSIS: 
It occurs in two clinical scenarios. 1.Patient treated by artificial 
pneumothorax and 2. post operative patients after lobectomy and 
pneumonectomy32.The diagnosis is made by demonstration of the 
aspergillus in the culture. 
 
BLASTOMYCOSIS: 
This presents similar to tuberculosis. It has both pulmonary 
infiltrate with accompanying effusion. The pleural effusion is an exudate 
and cytology is either neutrophils or lymphocytes. Pleural fluid 
biochemical parameters are significant for normal glucose and lactate 
dehydrogenase. 
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COCCIDIOIDOMYCOSIS: 
It is an exudate and produced by rupture of the cavity containing 
coccidioidomycosis. It characteristically produces hydropneumothorax. 
 
HISTOPLASMOSIS: 
It is a very rare cause of pleural effusion and produces an exudate 
type of pleural effusion with lymphocyte predominance. X ray reveals 
characteristic subpleural nodule. 
 
CANDIDIASIS: 
Esophageal perforation should be searched in any case associated 
with candidial effusion. It is usually seen in post -operative settings. 
 
ACTINOMYCOSIS: 
More than half of the patients with thoracic actinomycosisis 
associated with pleural effusion. Multiple draining sinus tracks give a 
clue to the etiology. Gram staining is useful in the demonstration of the 
organism.it may produce gross pus in the pleural cavity with neutrophils 
dominance or serous fluid with lymphocyte dominance. 
 
NOCARDIOSIS: 
Nocardiasis occurs in the setting of imunocompromised patients. It 
has pulmonary infiltrate and effusion.  
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ASBESTOS RELATED PLEURAL EFFUSION24: 
Probable pathogenesis of this relation is depostion of the asbestos 
in the pleural cavity stimulates the mesothelial cells to produce cytokines 
that acts as a chemoattractant for the neutrophils. Presence of pleural 
plaques and pleural calcification gives a clue to the diagnosis. About 10% 
of patients have bilateral pleural effusion. Effusion is usually mild to 
moderate and serous or serosanguineouswith high WBC count. 
 
POST LUNG TRANSPLANT EFFUSION: 
Due to the transection of lymphatics pleural effusion occurs 
commonly after lung transplantation. 
 
YELLOW NAIL SYNDROME: 
Characteristic feature of yellow nail syndrome is  
1) Yellow nails. 
2) Lymphedema. 
3) Pleural effusion. 
It occurs due to poorly formed lymphatics. Pleural effusion is 
bilateral in more than half of the patients. Pleural effusion usually recurs 
after draining the effusion. Nails give a vital clue to the diagnosis. 
Changes include color changes from yellow and thickened, often smooth 
and occasionally show ridges. The rate of nail growth is slow and 
onycholysis is present. 
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PLEURAL EFFUSION SECONDARY TO DISEASE OF HEART: 
1) CONGESTIVE CARDIAC FAILURE 
2) POST CORONARY ARTERY BYPASS SURGERY 
3) DRESSLER’S SYNDROME 
4) PERICARDIAL DISEASE. 
 
POST CORONARY ARTERY BYPASS SURGERY: 
Incidence of pleural effusion is high following post coronary 
bypass graft surgery. If performed using internal mammary artery the 
incidence is more than that occur with saphenous graft. Effusion can to 
the proportion of massive effusion and it is an exudate and lymphocyte 
predominant. Dyspnea is the common presentation. If the effusion 
occupies more than twenty five percent then needle aspiration is 
necessary to rule out other causes. 
 
DRESSLER’S SYNDROME: 
It is characterized by high temperature, pleuritic nature of chest 
pain, and pulmonary infiltrate after weeks following pericarditis or 
myocardial infarction. Around 4% of patients develop this syndrome 
following myocardial infarction. It is an exudative effusion, occurs 
commonly in second or third week post myocardial infarction. 
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PLEURAL DISEASES IN OBSTERICS AND GYNECOLOGY: 
1) OVARIAN HYPERSTIMULATION SYNDROME 
2) MEIG’S SYNDROME 
3) ENDOMETRIOSIS 
 
OVARIAN HYPERSTIMULATION SYNDROME: 
It is probably produced by vasoactive product that is produced 
during the induction of ovulation artificially by HCG. In this disorder 
ovary enlarges, with accumulation of fluid in the peritoneal cavity and 
pleural space with associated hypovolemia. The effusion is often right 
sided and exudative. The mean protein concentration in this syndrome is 
4.1 g/dL. 
 
MEIG’S SYNDROME: 
It occurs with benign ovarian neoplasms and those that occur from 
other cause Is called as Pseudo Meig’s syndrome. it is an exudate and 
resolves after treating primary ovarian tumor. 
 
ENDOMETRIOSIS: 
It is usually associated with ascites and effusion is haemorrhagic in 
most instances. Usually treated with hormonal therapy and it is difficult 
to cure in more than fifty percent of patients. Treated with hysterectomy 
with salphingo-oophorectomy. 
44 
 
CHYLOTHORAX: 
Chylothorax34 is defined as accumulation of lymph in the pleural 
space. It contains high concentration of triglyceride in the form of 
chylomicron particles. If there is accumulation of cholesterol it is called 
as pseudochyle or chyliform effusion. The milky appearance of the 
pleural chyle disappears during fasting.  
 
The causes of chylothorax: 
It can be due to either benign or malignant disorders and trauma. 
Malignant causes include 
1) Lymphoma. 
2) lung cancer. 
3) Mediastinal spread of  any malignant process 
Benign disorders: 
1) Lymphangioleiomyomatosis 
2) Intestinal lymphangiectasia 
3) Enteropthy 
4) Rarely cirrhosis of liver 
5) Tuberculosis 
6) Aneurysm of thoracic aorta 
7) Amyloidosis 
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TRAUMATIC ETIOLOGY: 
Surgery involving thoracic aorta, lung resection, esophageal 
surgery and Penetrating injuries to neck region presents with chylous 
effusion. 
CT scan, lymphangiography and lymphoscintigraphy is used as 
diagnostic tool for diagnosis. It is commonly managed with 
pleuroperitoneal shunt if it is due to malignancy. 
 
TRANSUDATIVE PLEURAL EFFUSIONS: 
CONGESTIVE CARDIAC FAILURE: 
It is the most common cause of pleural effusion. More than 80% of 
the pleural effusion occurs bilaterally35. Remaining patients have mostly 
right-sided effusion. Concepts of pleural fluid formation and reabsorption 
inpatients with heart failure have undergone significant modifications. 
Initially the fluid formation was proposed to be based in accordance with 
Starling’s law. Increased pressure in the capillaries in the visceral or the 
parietal pleura is present. These increased pressure were thought to result 
in an increased entry of fluid into the pleural space from the parietal 
pleura and a decreased removal of fluid through the visceral pleura. The 
current concept of pleural effusion in CCF is based on the theory that 
most of the fluid that enters the pleural space in patients comes from the 
alveolar capillaries rather than the pleural capillaries. 
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 When the pressure in the pulmonary capillaries is elevated 
increased amounts of fluid enters the interstitial spaces of lung. The 
increased interstitial fluid results in an increased interstitial pressure in 
the subpleural interstitial spaces. The fluid then moves from the 
pulmonary interstitial spaces across the visceral pleura into the pleural 
space. There appears to be relatively little resistance to fluid movements 
from the pulmonary interstitial spaces across the visceral pleura. Pleural 
fluid accumulates in patients with CCF when the rate of entry of fluid 
into the pleural space exceeds the capability of the lymphatics in the 
parietal pleura to remove the fluid. 
The pleural effusion in patients with heart failure is typically a 
transudate satisfying the Light’s criteria. In 15 to 20% of patients the 
pleural effusion is classified as exudate by Light’s criteria. Most patients 
who are misclassified are receiving diuretics therapy. If the effusion is 
thought to be due to heart failure then serum to pleural fluid protein 
gradient should be done. If this gradient is more than 3.1g/dL, the pleural 
effusion in all chances is due to heart failure.  
 
HEPATIC HYDROTHORAX: 
Hepatic hydrothorax is a pleural effusion (usually greater than 
500mL) caused by hepatic cirrhosis and portal hypertension in the 
absence of cardiopulmonary disease. Hepatic hydrothorax is usually 
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associated with ascites but can occur in its absence. Pleural fluid is almost 
always transudative. It occurs most commonly in the right side and rarely 
bilateral and left. Accumulation of fluid occurs due to the defects in the 
diaphragm that enable the fluid in the peritoneal cavity to move in to the 
pleural cavity due the negative pressure in the pleura. 
CHARACTERISTIC OF HEPATIC HYDROTHORAX: 
1) Right side(85%) 
2) Left side(13%) 
3) Bilateral(2%) 
 
FLUID: 
1) Cell count <250 PMN cells  
2) Protein <2.5g/dL 
3) Serum to pleural fluid albumin gradient >1.1 
4) pH>7.4 
5) Pleural fluid/serum bilirubin ratio<0.6 
 
NEPHROTIC SYNDROME: 
Nephrotic syndrome is a well-known cause of transudative pleural 
effusion. The overall incidence is about 20%. Pleural effusion in patients 
with nephrotic syndrome is usually bilateral. Pulmonary embolism occurs 
at a higher rate with the nephrotic syndrome and this etiology for the 
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pleural effusion should be excluded in all patients with nephrotic 
syndrome.  
 
HYPOALBUMINEMIA: 
Hypoalbuminemia per se is not a cause of clinically significant 
transudative pleural effusion. In patients with cirrhosis with 
hypoalbuminemia and absence of ascites, pleural effusion is rarely 
encountered. 
 
URINOTHORAX: 
Urinothorax36 denotes presence of urine in the pleural space. This 
condition is due to ipsilateral obstructive uropathy resulting in 
retroperitoneal leakage of urine. The pleural fluid looks and smells like 
urine. The pH is usually less than 7.2 and protein level is usually less than 
1.0 gm/dL. Pleural fluid glucose is usually normal or below but effusion 
contains markedly elevated LDH. Pleural fluid creatinine is usually 
greater than the serum creatinine.  
 
PERITONEAL DIALYSIS: 
Transudative pleural effusions are occasionally encountered in 
patients undergoing peritoneal dialysis. The pleural fluid in these patients 
is characterized by a glucose level intermediate between that of the 
49 
 
dialysate and the serum, protein level below 3gm/dL, and low LDH 
whichis higher than that in the ascitic fluid. 
 
MYXEDEMA: 
Pleural effusion occasionally occurs as a complication of 
myxedema. When pleural effusion occurs simultaneously with a 
pericardial effusion, the pleural fluid is usually a transudate. The isolated 
pleural effusion secondary to hypothyroidism is either exudate or 
transudate.  
 
C-REACTIVE PROTEIN(CRP):  
Acute phase reactants are defined as those proteins whose serum 
concentrations increase or decrease by atleast 25% during inflammatory 
states. They are usually produced in the liver. These may increase called 
positive acute phase reactants or decrease which are called negative acute 
phase reactant. 
Increase in concentration of acute phase reactants comprises a 
major pathophysiologic phenomenon that accompanies inflammation and 
tissue injury. C-reactive protein belongs to acute phase reactant group 
which rises during the inflammatory process. CRP consists of five 
identical non-covalently linked subunits, each with a molecular weight of 
approximately 23kD, which are arranged symmetrically around a central 
pore. CRP and related proteins with this structure are termed pentraxins.  
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Its production is stimulated by IL-6, which is produced by macrophage 
system and adipocytes. CRP binds to phosphocholine on the microbes. It 
helps in enhancing compliment activity and phagocytosis of macrophage 
system. Determining the level of CRP is simple, quick, and cheap. 
CRP riseupto 50,000 times in acute inflammation, particularly 
infection. Within 6 hours the level of CRP level start to rise. The value of 
CRP peaks at forty -eight hours. The half-life of CRP is constant. The 
severity and the rapidity with which the disease develops determine the 
level of CRP.  
 
THE ROLE OF CRP IN PLEURAL EFFUSION: 
Hoda Abu-Yosssef et al conducted a study of CRP protein in 
exudative pleural effusion and to find the diagnostic value of it on forty 
Patients. The study found a significant difference for mean values of high 
sensitive CRP between exudative and transudative effusion.  
Yilmaz et al. found the discrimination39-42 between exudate and 
transudate pleural effusions with sensitivity and specificity for fluid CRP 
was 93.7% and 76.5%, respectively. 
Study conducted by Alexandrakis et al. found that CRP in pleural 
fluid were significantly higher in exudates than in transudate effusion 
In many studies it was found CRP43-46 level critically high in tubercular 
and parapneumonic effusions than in other causes of pleural effusion. The 
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determination of CRP is useful in the diagnostic pleural effusion with 
predominant lymphocytosis.  
Virdahis and Amores et al. found fluid CRP level was twice as 
higher in tuberculous than in malignancy. 
Yilmaz et al. concluded that CRP in pleural fluid and pleural fluid 
–serum ratio of CRP is useful in workup of various effusions such as 
parapneumonic, tuberculous, and malignant effusions. 
Garcia E Pachon found pleural fluid CRP is higher in benign when 
compared to malignant effusions. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
MATERIALS AND METHODS 
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MATERIAL AND METHODS 
SETTING: 
This study was conducted at the Institute of Internal Medicine, 
Rajiv Gandhi Government General Hospital, and Madras Medical 
College. 
 
ETHICAL COMMITTEE APPROVAL: 
Obtained. 
 
STUDY DURATION: 
This study was conducted over a period of six months. 
 
STUDY POPULATION: 
Patients admitted with pleural effusion in medical wards, Institute 
of  Internal medicine. 
 
SAMPLE SIZE: 
Fifty cases admitted with pleural effusion. 
 
TYPE OF STUDY: 
Cross sectional study: 
 
INCLUSION CRITERIA: 
• Newly detected cases of pleural effusion. 
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EXCLUSION CRITERIA: 
• Patients not willing to consent. 
• Patients taking oral contraceptives. 
• Patients with collagen vascular diseases on treatment. 
• Patients with HIV and AIDS. 
 
DATA COLLECTION AND METHODS: 
Patients have their history taken according to questionnaire and 
subjected to clinical examination. All patients with clinical and x ray 
diagnosis of pleural effusion underwent pleural fluid analysis comprising 
of protein, sugar, LDH, ADA, cytology, AFB, culture. Renal function 
tests, complete blood count, liver function tests, serum protein and LDH, 
sputum gram stain and culture and sensitivity. CRP was measured in all 
cases of pleural effusion. Light’s criteria was used to classify the patients 
into exudate and transudate. Transudate group were further subjected to 
find the cause of transudate by subjecting them to ultrasound abdomen, 
echocardiogram. Exudative pleural effusion was studied under four 
categories-parapneumoniceffusion, tuberculous effusion, malignant 
effusion, and others. Each of these were defined by definite criteria for 
the purpose of study. Parapneumonic effusion is defined by signs and 
symptoms of pneumonia with characteristic infiltrate radiologically with 
or without positive gram stain and culture of blood or pleural fluid 
cytology with neutrophilic predominance with negative sputum AFB and 
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low ADA levels with no clinical evidence of other cause and clinical 
improvement with antibiotic theraphy. Tuberculous effusion defined by 
absence of evidence for bacterial pneumonia and ADA>40 IUwith or 
without reactive mantoux test with or without positive sputum or pleural 
fluid AFB. Pleural fluid biopsy with granuloma was taken as final in the 
absence of above investigations. Malignant effusion was diagnosed by 
positive cytology of pleural fluid for malignant cells or biopsy proven or 
haemorrhagic effusion in known case of malignancy. All data were 
entered in proforma (enclosed) 
 
STATISTICAL ANALYSIS 
Descriptive statistics were used for presenting the patient 
characteristics. All data would be subjected to  FISHER’S EXACT 
TEST, UNPAIRED ‘t’ and ANOVA tests. Individual group comparisons 
would be made using parametric tests and non-parametric tests as 
appropriate. P value of <0.05 is taken as significant in this study. 
Statistical analysis was done with GRAPH PAD PRISM software. 
 
  
  
 
 
OBSERVATIONS AND ANALYSIS 
  
 OBSE
TOTAL CASES:  
Total number of patients taken up for study was 50. A
fifty patients 11 belonged to transudate and 39 belonged to exudate 
category of pleural effusion. In percentage 22% were transudate and 78% 
were exudate.  
TABLE 1: CASE DISTRIBUTION
CASES 
TRANSUDATE
EXUDATE 
 
CHART 1-CASE DISTRIBUTION
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NO. OF CASES % OF CASES
 11 
39 
 
TRANSUDATE
EXUDATE
NO. OF CASES
 
mong the 
 
22% 
78% 
 
 TABLE 2:SEX DISTRIBUTION:
SEX
MALE
FEMALE
 
 
CHART -2: SEX DISTRIBUTION
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 NO. OF CASES
 33 
 17 
 
 
MALE
66%
FEMALE
34%
NO. OFCASES
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SYMPTOM ANALYSIS: 
The total number of patients who had cough- 48%,sputum-44%, 
hemoptysis -3%, fever- 23%, and loss of weight- 13%. 
In parapneumnoic effusion, cough with sputum production was 
present in 82.3% and 5.8% had hemoptysis and 94.1% patient had fever. 
In tuberculosis group, only 21% had cough, and none of them had 
hemoptysis and fever was present in 35.7% and loss of weight was 
present in 35.7%. 
 
TABLE 3:SYMPTOM ANALYSIS 
 
NO. OF 
PATIENTS 
PERCENTAGE 
COUGH 24 48 
SPUTUM 22 44 
HEMOPTYSIS 3 6 
FEVER 23 46 
LOSS OF WEIGHT 13 26 
 
 
 
 
 
 
 
 
 CHART 3: SYMPTOM ANALYSIS OF ALL PATIENTS
 
 
TABLE:4   PARAPNEUMONIC EFFUSION
ANALYSIS: 
 
COUGH 
SPUTUM 
HEMOPTYSIS 
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- SYMPTOM 
NO.OF CASES PERCENTAGE
14 
14 
1 
16 
 0 
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5.8 
94.1 
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 CHART:4 PARAPNEUMONIC EFFUSION
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 TABLE: 5 TUBERCULOUS PLEURAL EFFUSION
 
COUGH 
SPUTUM 
HEMOPTYSIS
FEVER 
LOSS OF WEIGHT
 
CHART:5 TUBERCULOUS PLEURAL EFFUSION
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NO.OF CASES PERCENTAGE
3 
4 
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5 
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21 
28.5 
0 
35.7 
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Series 1
 TABLE: 6 MALIGNANT PLEURAL EFFUSION
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SPUTUM 
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FEVER 
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 SYMPTOMS
NO.OF CASES PERCENTAGE
4 
2 
 2 
2 
 8 
EURAL EFFUSION SYMPTOMS
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 TABLE:7  CAUSE
TRANSUDATE 
HEART FAILURE
DCLD 
 
 
CHART: 7   CAUSES OF TRANSUDATIVE EFFUSION
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NO.OF CASES
 9 
2 
 
 
82%
18%
NO. OF CASES
HEART FAILURE DCLD
: 
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TABLE:8  CAUSES OF EXUDATIVE PLEURAL EFFUSION : 
 
EXUDATE NO.OF CASES 
TUBERCULOSIS 14 
PARAPNEUMONIC EFFUSION 17 
MALIGNANCY 8 
 
CHART :8   CAUSES OF EXUDATIVE PLEURAL EFFUSION 
 
 
  
36%
44%
20%
NO. OF CASES
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AGE DISTRIBUTION OF PLEURAL EFFUSION 
The majority of patient belonged to 50-60 years: 
TABLE: 9  AGE  DISTRIBUTION 
AGE IN YEARS NO. OF CASES 
20-30 9 
30-40 12 
40-50 12 
50-60 17 
 
TABLE: 10 AGE DISTRIBUTION 
PLEURAL FLUID 
CHARACTER 
MEAN AGE SD OF AGE 
EXUDATE 43 8.60 
TRANSUDATE 43.48 11.90 
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TRANSUDATIVE PLEURAL EFFUSION: 
CHARACTERISTICS: 
The mean ESR among the transudate group were15.6 mm/hr(SD-
7.52). Serum LDH were 85.81 IU/L(SD-40.06) and LDH ratio was 
0.41(SD-0.10). Mean Pleural fluid protein was 1.65 (SD-0.64)and the 
protein ratio was 1.65. Mean Pleural fluid ADA 15.54 IU. Mean pleural 
fluid CRP was 7.21mg/L(SD-2.27) 
TABLE:11 TRANSUDATE EFFUSION LAB FEATURES 
VARIABLE MEAN SD 
ESR (mm/hr) 15.6 7.52 
SERUM LDH(IU/L) 85.81 40.06 
PF PROTEIN 1.65 0.64 
PROTEIN RATIO 0.30 0.09 
PF LDH(IU/L) 34.72 16.56 
LDH RATIO 0.41 0.10 
PF ADA(IU/L) 15.54 3.67 
PF CRP(mg/L) 7.21 2.27 
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EXUDATIVE PLEURAL EFFUSION: 
TUBERCULOSIS: 
TABLE:12 TUBERCULOSIS SEX DISTRIBUTION 
SEX NO.OF CASES 
MALE 8 
FEMALE 6 
 
TABLE:13 TUBERCULOSIS- LAB FEATURES 
VARIABLE MEAN SD 
AGE 47.5 12.23 
ESR mm/hr 39.28 25.17 
SERUM LDH(IU/L) 180.64 45.55 
PF LDH(IU/L) 198.42 83.10 
LDH RATIO 1.24 0.73 
PF PROTEIN (g/dL) 3.78 0.51 
PROTEIN RATIO 0.71 0.07 
PF ADA(IU/L) 50.5 8.89 
PF CRP(mg/L) 52.15 14.83 
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TUBERCULOUS PLEURAL EFFUSION ANALYSIS: 
The ESR of this group is 39.28mm/hr.(SD-25.17) Mean serum 
LDH and LDH ratio was 198.42IU/L(SD-83.10) and 1.24IU/L(SD-0.73) 
respectively. The pleural fluid protein and protein ratio was 3.78(SD-
0.51) and 0.71(SD-0.07). Pleural fluid CRP ADA was 50.5IU/L(SD-
8.89). 
PLEURAL FLUID CYTOLOGY: 
The cytology of pleural fluid in tubercular group were mostly 
lymphoctyte predominant, and three were surprisingly having 
predominant polymorphs. 
 
TABLE:14  TUBERCULOSIS PLEURAL FLUID CYTOLOGY - 
CYTOLOGY NO. OF CASES % OF CASES 
LYMPHOCYTE 9 65 
PMN 3 21 
NORMAL 2 14 
 
 
 
 
 
 
 CHART:9  TUBERCULOSIS
 
 
PARAPNEUMONIC EFFUSI
Parapneumonic effusions were predominantly present in male in 
this study. With sixteen out of seventeen patients are male. And ESR was 
elevated and mean ESR was 34.17(SD
elevated and mean serum LDH 273.58 
highly elevated and mean value was 420.29 
satisfying the criteria of exudate and mean value was 1.565. 
fluid ADA was not significantly elevated as expected and mean was 
23.70 IU. 
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TABLE:15 PARAPNEUMONIC EFFUSION 
 MEAN SD 
AGE 39.82 12.28 
 
SEX MALE FEMALE 
NO. OF CASES 16 1 
 
VARIABLE MEAN SD 
ESR (mm/hr) 34.17 8.71 
SERUM LDH(IU/L) 273.58 94.14 
PF LDH(IU/L) 420.29 231.05 
LDH RATIO 1.565 0.65 
PF PROTEIN(g/dL) 4.59 0.97 
PROTEIN RATIO 0.743 0.12 
PF ADA (IU) 23.70 10.57 
PF CRP(mg/L) 103.47 32.23 
 
PLEURAL FLUID CYTOLOGY: 
The cytology of pleural fluid is predominantly 
polymorphonuclearcells. 
 
 TABLE:16 PARAPNEUMONIC EFFUSION CYTOLOGY
CYTOLOGY 
PMN 
NORMAL 
 
CHART: 10 PLEURAL FLUI
PARAPNEUMONIC EFFUSION
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MALIGNANT EFFUSION: 
The mean ESR of malignant effusion is 15.5mm/hr(SD-6.11). The 
serum LDH is 178.75IU(SD-45.35). The total protein and protein ratio is 
3.125g/dl (SD-0.575) and 0.62(SD-0.13). The mean pleural fluid ADA is 
14.75IU(SD-5.47).  
 
TABLE:17   MALIGNANT EFFUSION 
AGE MEAN SD 
 44.87 14 
 
SEX MALE FEMALE 
NO. OF CASES 3 5 
 
VARIABLE MEAN SD 
ESR(mm/hr) 15.5 6.11 
SERUM LDH (IU) 178.75 45.35 
PF LDH(IU) 245.75 99.42 
LDH RATIO 1.366 0.45 
PF PROTEIN(g/dL) 3.125 0.575 
PROTEIN RATIO 0.62 00.13 
PF ADA (IU) 14.75 5.47 
PF CRP(mg/L) 23.075 7.83 
 
 TABLE: 18 P VALUE FOR TRANSUDATIVE AND EXUDATIVE 
EFFUSION: 
VARIABLE 
AGE 
SEX 
ESR 
SERUM LDH
PF LDH 
LDH RATIO 
PF PROTEIN
PROTEIN RATIO
ADA 
CRP 
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P VALUE SIGNIFICANCE
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 CHART:12   PROTEIN RATIO:
CHART:13   PLEURAL FLUID
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 LDH 
PARAPNEUMONIC 
EFFUSION
MALIGNANCY
EXUDATE
 
 
MEAN
SD
MEAN
SD
 CHART:14    PLEURAL FLUID LDH IN EXUDATIVE PLEURAL 
EFFUSION
 
 
CHART:15 LDH RATIO
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PARAPNEUMONIC 
EFFUSION
MALIGNANCY
PARAPNEUMONIC 
EFFUSION
MALIGNANCY
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CHART:16   CRP
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 IN PLEURAL EFFUSION 
 IN EXUDATIVE EFFUSION 
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 TABLE:19  ESR 
 
TB vs  PPE 
TB vs  ME 
PPE vs ME 
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DIFFERENCE 
P VALUE CONFIDENCE 
5.11 >0.05 
23.780 <0.01 
18.670 <0.05 
TB vs ME PPE vs ME
95% 
INTERVAL 
-9.281 TO 
19.501 
6.107 TO 
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1.5742 TO 
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CHART:19  CRP 
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MEAN 
DIFFERENCE 
P VALUE CONFIDENCE 
51.320 <0.001 
+29.08 <0.05 
+84.40 <0.001 
 
 
TB vs ME PPE vs ME
CRP
95% 
INTERVAL 
-72.08 TO -
30.558 
3.583 TO 
54.577 
5.735 TO 
105.06 
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TABLE:20   PLEURAL FLUID LDH 
 
MEAN 
DIFFERENCE 
P VALUE 
95% 
CONFIDENCE 
INTERVAL 
TB vs  PPE -75.160 >0.05 
-155.86 TO 
5.540 
TB vs  ME -47.330 >0.05 
-146.43 TO 
51.772 
PPE vs ME +27.830 >0.05 
-68.035 TO 
123.70 
 
TABLE: 21  PLEURAL FLUID LDH RATIO 
 MEAN P VALUE 
95% 
CONFIDENCE 
INTERVAL 
TB vs  PPE -0.3232 >0.05 
-0.8951 TO 
0.2487 
TB vs  ME -0.1242 >0.05 
-0.8265 TO 
0.5781 
PPE vs ME 0.1990 >0.05 
-0.4804 TO 
0.8784 
 
 TABLE:22  PLEURAL FLUID 
 
TB vs  PPE 
TB vs  ME 
PPE vs ME 
 
CHART 21: PLEURAL FLUID ADA
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 ADA 
MEAN 
DIFFERENCE 
P VALUE CONFIDENCE 
26.800 <0.001 
34.960 <0.001 
8.160 <0.05 
 
TB vs ME PPE vs ME
95% 
INTERVAL 
21.234 TO 
32.366 
28.125 TO 
41.725 
1.548 TO 
14.772 
 
 CHART:22  ADA 
 
PLEURAL FLUID PROTEIN: 
The pleural fluid protein content was significant for 
Malignant effusion and parapneumonic effusion vs malignant effusion.
 
TABLE:23  PLEURAL FLUID PROTEIN
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PROTEIN RATIO: 
The protein ratio was significant for insignificant for TB vs 
parapneumonic effusion and TB vs malignant effusion.  
CHART:23 PLEURAL FLUID PROTEIN RATIO 
 MEAN P VALUE 
95% 
CONFIDENCE 
INTERVAL 
TB vs  PPE -0.330 >0.05 
-0.1275 TO 
0.06150 
TB vs  ME 0.0900 >0.05 
-0.02604 TO 
0.02060 
PPE vs ME 0.1230 <0.05 
0.01074 TO 
0.2353 
 
TB- TUBERCULOSIS 
ME-MALIGNANT EFFUSION 
PPE-PARAPNEUMONIC EFFUSION 
S- SIGNIFICANT 
NS – NOT SIGNIFICANT 
  
  
 
 
DISCUSSION 
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DISCUSSION  
ETIOLOGY OF PLEURAL EFFUSION:  
In our study the most common etiology of pleural effusion is 
parapneumonic effusion, next in frequency is tuberculous. Exudative 
pleural effusion is more common than the transudative pleural effusion. 
According to western literature, congestive cardiac failure is the most 
common cause of pleural effusion but several studies do not include 
congestive cardiac failure in the study of pleural effusion, so the true 
incidence of the cardiac failure is not known. Our study shows incidence 
of tuberculous effusion is 28%vs 32.5% in other studies. 
Parapneumonic effusion is 34% vs 19% in other studies. Having 
taken consecutive patients heart failure associated pleural effusion is 
surprisingly when compared to other studies. In a study done in India 
titled “Exudative pleural effusions in patients over forty years of age” 
malignant effusion is the most common cause followed by tuberculosis. 
All patients with malignant effusions were more than 40 years of age. 
The incidence of hepatic hydrothorax in our study is 4% vs 3% in an     
other study. Our study though evaluated fifty consecutive patients it did 
not find any rare cause of pleural effusion such as pleural effusion in 
hypothyroidism, lupus, rheumatoid arthritis, nephrotic syndrome. 
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AGE( yrs) AND SEX: 
Mean age of exudative pleural effusion is 43.61yrs(SD-12.77). The 
mean age of transudative effusion is 43(SD-8.60). The mean age of 
tuberculous effusion is 47.5 vs 33.7 in other study. The mean age of 
parapneumonic effusion is 39.82 vs 43.3 in other studies. In our study 
tuberculous effusion is ten years more than the previous study, but 
tuberculous effusion typically occursin20-40 age group in Indian 
subcontinent. 
The mean age of malignant effusion is 44.87yrsvs 53.4 in previous 
study. In our study males were 33 in number and females were 17 in 
number. This does not vary with other studies and not statastically 
significant. There was no statistical significance in the age between the 
transudate and exudate category.  
 
SYMPTOM ANALYSIS: 
The symptoms that were analyzed were cough, sputum production, 
hemoptysis, fever, loss of weight. 
Cough was the most common symptom present. Followed by fever 
and sputum production. Hemoptysis was present only in 6% of patients.  
Interestingly, tuberculous patients did not have any hemoptysis and this 
shows pleural effusion as a primary modality of presentation in patients 
with tuberculosis by hypersensitivity reaction to tubercular proteins rather 
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than the extension of caseating focus in the lung. Fever was present in 
only 35.7% of tuberculous effusion patient whereas 94% of patients with 
parapneumoniceffusion had fever during the presentation.  In a study 
published by BansalPankaj et al. where they studied 250 cases of 
tuberculous effusion the common symptoms were fever, cough, 
breathlessness followed by chest pain. Fever is important in the diagnosis 
of parapneumonic effusion and the persistence of fever more than fourty 
eight hours of therapy indicates complicated parapneumonic effusion. 
The absence of fever or chest pain should not stop us from considering 
parapneumonic effusion. Sahn et al. reported cases where empyema 
caused by aerobes did not have fever. Patients with anaerobic bacterial 
effusion need not have the dramatic presentation of the aerobic organisms 
and disease any have a subacute illness. 
Malignant pleural effusion is second most common cause of 
exudative pleural effusion in many series. The most common symptom of  
malignant effusion is breathlessness and in one study, weight loss was 
about 32% whereas in our study the incidence of weight loss is 100%. 
Hemoptysis was present in 25% of malignant effusion when compared to 
other series where hemoptysis was present in more than 40% of patients. 
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ERYTHROCYTE SEDIMENTATION RATE(ESR): 
ESR of the transudate group is 15.6mm/hr(SD-7.52), tuberculosis 
has an ESR of 39.28mm/hr(SD-25.17), parapneumonic effusion ESR- 
34.17mm/hr(SD-8.71) and Malignant effusion has an ESR of 
15.5mm/hr(SD-6.11) 
The normal upper value of ESR in male is 15mm in first hour and 
that of females is 20mm in first hour. Many studies have proven the value 
of ESR in the diagnosis of tuberculosis. In our study ESR in tuberculosis 
is significantly higher than in other effusions, it can also be used for 
follow up of treatment. The ESR is significant in our study differentiating 
tuberculous from malignant effusion with a P value of <0.01. 
 
PLEURAL FLUID LDH(IU/L) AND LDH RATIO: 
The mean of pleural fluid LDH is 34.72IU/L(SD-16.56) in 
transudate group and when compared with exudate it is extremely 
significant. 
Pleural fluid LDH in tuberculosis, parapneumonic effusion, and 
malignancy is 194.42IU(SD-83.10), 420.29IU(SD-231.05), and 
245.75IU(SD-99.42) respectively. 
It is highest in parapneumonic effusion. In comparison with our 
study exudative pleural effusion has LDH value more than 200 IU/L.  
86 
 
In a study done by Manuel Vives et al LDH more than 300IU/L had a 
sensitivity of 87.4% and specificity of 87.2% and a positive predicitive 
value of 96.3% and diagnostic accuracy of 87.4%. Differentiating 
between LDH based on the LDH alone is not significant according to our 
study. LDH ratio was also not useful in differentiating different types of 
exudate but it is statistically significant in differentiating exudate and 
transudate effusion. LDH ratio has 94.2% diagnostic accuracy according 
to various studies. Though our study did not have absolute LDH value 
more than 1000IU/L, presence of this high value indicates high tumor 
burden or empyema. 
 
PLEURAL FLUID TOTAL PROTEIN (g/dL) AND PROTEIN RATIO:  
The pleural fluid protein in transudate is 1.65g/dL(SD-0.64) and in 
parapneumonic effusion is 4.59g/dL(SD-0.97), malignant effusion is 
3.125g/dL(SD-0.575), tuberculous effusion is 3.78g/dL(SD-0.51). As 
expected pleural fluid protein is higher in exudates when compared to 
transudate,and statistically significant for comparing the two. 
 
PROTEIN RATIO: 
The protein ratio in transudate is is 0.30(SD-0.09). In tuberculosis 
ratio is 0.71(SD-0.07), in parapneumonic effusion, ratio is 0.743(SD-
0.12) in malignancy the ratio is 0.62(SD-0.13). All three exudative 
effusion satisfy the lights criteria. 
87 
 
 
PLEURAL FLUID ADA (IU/L): 
The mean pleural fluid ADA in transudate group is15.54 IU (SD-
2.27). The mean pleural fluid ADA in tuberculosis, parapneumonic 
effusion, and malignancy is 52.15IU(SD-14.83),23.70IU(SD10.57)), and 
23.O75 IU(SD-7.83) respectively. ADA level was significantly higher in 
tuberculosis and more than the diagnostic cut off of 40 IU/L. In various 
studies done both in India and western countries ADA remains cost 
effective diagnostic modality for tuberculous effusion. IN study done in 
Nepal mean pleural fluid ADA was about 90.29IU(SD-54.80). Our study 
had lesser ADA than the study done at Nepal. ADA level is defined only 
in the pleural fluid and the measurement of ADA in other body fluid 
needs further validation. 
 
PLEURAL FLUID CRP: 
Our study aimed at bringing out the significance of CRP in the 
etiological diagnosis of pleural effusion. Comparing the mean CRP 
between the transudative and exudative effusion is extremely significant 
with the P value of <0.0001. Study conducted by us had a mean CRP-
7.21mg/L(SD-2.27) in transudative group. Study conducted by Castano et 
al. showed mean pleural fluid CRP around 5.3mg/L(SD-7.8) in transudate 
group and it was significantly lower than the exudate group. Our study 
was extremely significant differentiating the two. 
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In study conducted by Hoda et al. the mean serum value was 
0.30(SD-0.11) and the stastical significance with P<0.0039. 
The exudate group had mean CRP value of 68.55mg/dL(SD-
40.04).The mean pleural fluid CRP in exudative group in an other study 
is 67.6mg/L(SD-6.74). Most of the studies also attempted also attempted 
to measure the corresponding CRP in the serum and determined the CRP 
ratio. The mean of the CRP ratio in transudative group is 0.14mg/dL(SD-
0.11) and the exudative pleural fluid CRP 0.39(SD-0.34) 
But the pleural fluid to serum CRP ratio was not significant in this 
study. In other study done, CRP ratio in transudative effusion had median 
value of 0.34 and mean is 0.36(SD-0.19). 
 
CRP IN EXUDATIVE PLEURAL EFFUSION: 
The mean CRP in pleural fluid among different groups of exudate 
in our study is tuberculosis-52.15mg/L(SD-14.83), Parapneumonic 
effusion-103.47mg/L(SD-32.23), malignancy-23.07mg/L(SD-7.83). In a 
study conducted in Spain the mean CRP in malignant process is 
29.3mg/L(SD-16.1), parapneumonic effusion-122.7mg/L(SD-48) and in 
tuberculosis group the mean CRP is 67.8mg/L(SD-32.1). 
Parapneumonic effusion had the highest CRP in exudative group 
and it is more than tuberculosis. Malignant pleural effusion had lower 
CRP level in pleural fluid compared to others in exudative group.  
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COMPARISON OF CRP IN TUBERCULOUS AND 
PARAPNEUMONIC EFFUSION: 
Statistics done by one way ANOVA (Analysis of variance). The 
mean difference between tuberculosis vs parapneumonic effusion is – 
51.320. The P value is significant and <0.001. 
 
COMPARISON OF CRP IN TUBERCULOUS EFFUSION AND 
MALIGNANT EFFUSION: 
The mean difference between tuberculosis and malignancy group is 
+29.080 and p value is significant <0.05% 
 
COMPARISION OF PARAPNEUMONIC EFFUSION AND 
MALIGNANCY: 
The P value is <0.001 and highly significant.Various other studies 
performed with CRP in pleural effusion are in concurrence with our study 
results. From the above analysis of CRP, it is evident that CRP has a 
discriminating role in not only exudative from transudative effusion. It 
also has a significant role in differentiating role in parapneumonic 
effusion from malignant effusion and tuberculous effusion from 
malignant effusion. 
  
  
 
 
CONCLUSIONS 
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CONCLUSION 
 
 Pleural fluid CRP levels are useful in differentiating exudative and 
transudative effusion.  
 Pleural fluid CRP level is elevated in all types of exudative 
effusion 
 Among the exudative group CRP level is highest in parapneumonic 
effusion. 
 If the pleural fluid CRP is more than 7.21 + 2.27 transudative 
effusion is unlikely. 
  If the pleural fluid CRP is more than 103.47 +32.23 parapnemonic 
effusion is more likely. 
 If the Pleural fluid CRP is more than 52.15 + 18.83 the diagnosis 
of tuberculous effusion  is strongly considered. 
 Pleural fluid CRP can be used to differentiate tuberculous from 
malignant pleural effusion. 
 CRP can be incorporated in algorithm of pleural fluid evaluation in 
routine practice. 
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PROFORMA 
ROLE OF PLEURAL FLUID C-REACTIVE PROTEIN 
ESTIMATION IN ETIOLOGICAL DIAGNOSIS OF PLEURAL 
EFFUSION 
Name:     Age:   Sex: 
Address:     Occupation: 
Symptoms: 
Cough Fever 
Expectoration Loss of weight/loss of appetite 
Dyspnoea Symptoms of volume overload 
Chest pain Symptoms of organ dysfunction 
 
Past history: 
Diabetes Chronic kidney 
disease 
Tuberculosis 
Hypertension Liver disease Malignancy  
Coronary artery 
disease/CCF 
Drug intake Collagen vascular 
disease 
 
Personal history: 
• Smoking 
• Alcoholism 
• Occupation  
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General examination: 
PULSE: 
BLOOD PRESSURE: 
GENERAL EXAMINATION: 
 
SYSTEMIC EXAMINATION: 
CVS: RS: ABDOMEN: CNS: 
 
INVESTIGATIONS: 
Hemogram RFT 
TC  cells/mm3 Glucose (F)  mg/dl 
DC  Glucose (PP)  mg/dl 
ESR  mm/hr Urea  mg/dl 
Hb  g/dl Creatinine  mg/dl 
PCV  % Na+  mEq/l 
Platelets  lakhs/mm3 K+  mEq/l 
RBCs  million/mm3 Others  
Liver function tests 
Total 
bilirubin 
 mg/dl Serum LDH  
Direct 
fraction 
 mg/dl HIV  
SGOT  IU/L Blood C/S  
SGPT  IU/L RF/ANA/TFT  
ALP  IU/L Sputum AFB  
Protein   g/dl Sputum C/S  
Albumin  g/dl Mantoux  
99 
 
 
PLEURAL FLUID ANALYSIS 
Sugar AFB 
Total protein and ratio C/S 
LDH and LDH ratio Gram’s stain 
Cytology ADA 
Cell count CRP 
 
CHEST X RAY 
 
CT CHEST 
 
PLEURAL/TISSUE BIOPSY 
 
ULTRASONOGRAM OF KIDNEYS: 
 
ECG: 
 
ECHO CARDIOGRAM: 
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PATIENT CONSENT FORM 
 
Study Detail : ROLE OF PLEURAL FLUID C-REACTIVE 
PROTEIN ESTIMATION IN ETIOLOGICAL 
DIAGNOSIS OF PLEURAL EFFUSION   
Study Centre : Rajiv Gandhi Government General Hospital, 
Chennai. 
Patient’s Name :  
Patient’s Age :  
Identification 
Number 
:  
Patient may check (☑) these boxes 
I confirm that I have understood the purpose of procedure for the 
above study. I have the opportunity to ask question and all my 
questions and doubts have been answered to my complete 
satisfaction. ❏ 
I understand that my participation in the study is voluntary and that I 
am free to withdraw at any time without giving reason, without my 
legal rights being affected. ❏ 
I understand that sponsor of the clinical study, others working on the 
sponsor’s behalf, the ethical committee and the regulatory authorities 
will not need my permission to look at my health records, both in 
❏ 
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respect of current study and any further research that may be 
conducted in relation to it, even if I withdraw from the study I agree 
to this access. However, I understand that my identity will not be 
revealed in any information released to third parties or published, 
unless as required under the law. I agree not to restrict the use of any 
data or results that arise from this study. 
I agree to take part in the above study and to comply with the 
instructions given during the study and faithfully cooperate with the 
study team and to immediately inform the study staff if I suffer from 
any deterioration in my health or well being or any unexpected or 
unusual symptoms. ❏ 
I hereby consent to participate in this study. ❏ 
I hereby give permission to undergo complete clinical examination 
and diagnostic tests including hematological, biochemical, 
radiological tests. ❏ 
Signature/thumb impression 
Patient’s Name and Address:Signature of Investigator 
Study Investigator’s  name: 
 
Dr. R. VICKRAM VIGNESH 
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S.NO AGE SEX COUGH SPUTUM HEMOPTYSIS FEVER LOW TC ESR SPUTUM GM SPUTUM CS SPUTUM AFB SERUM LDH SERUM PROTEIN Pl SUGAR Pl PROTEIN Pl LDH
1 25 M P P A P P 13000 68 A A P 110 5 40 4 310
2 28 M P A P P P 8000 16 A A A 250 6 50 3.2 360
3 32 M P P A P A 20000 24 P P A 160 5.7 60 3 250
4 33 F A A A A A 4000 20 A A A 47 6 90 2 20
5 23 F A A A A P 9000 76 A A A 172 4.6 50 3.1 298
6 60 F A A A A P 13500 30 A A A 200 6 50 3.2 320
7 34 M P P P P A 23600 46 P P A 400 7 59 5.3 1000
8 45 M P P A A A 4800 24 A A A 78 4.6 110 1.2 25
9 56 M A A A A A 5200 16 A A A 110 6 80 2.1 45
10 56 M A P A P A 11020 8 A A A 230 5.6 40 4.1 290
11 58 M P P A P A 28300 30 P P A 456 5.7 59 5 239
12 39 M P P A P A 32300 32 P P A 342 6.1 70 5 609
13 50 M P P A P A 19100 40 A A A 432 4.9 67 3 807
14 45 M A A A P A 20400 20 A A A 342 5.6 53 4 432
15 45 M A A A A A 6600 10 A A A 120 5.6 90 1.2 45
16 49 M A A A A A 8000 20 A A A 29 4 110 0.6 10
17 42 F A A A A A 6200 28 A A A 127 4.1 69 1.3 59
18 27 F A A A A A 4100 14 A A A 120 5.8 89 2 40
19 37 F A A A P A 11000 70 A A A 231 5.5 50 4.1 167
20 54 M P P A P A 2100 40 A A A 243 6.1 30 4.2 399
21 35 M A A A P A 19200 44 A A A 213 5.7 45 5 680
22 60 M P P A P A 21200 34 A P A 159 5.7 23 3 239
23 26 M P P A P A 22300 28 P P A 200 6.4 60 4.5 342
24 56 M P P A A A 10100 50 A A A 134 5.8 64 3.6 204
25 60 F P P A A A 9200 24 A A P 153 6.1 70 4.5 205
26 50 F A A A A A 6200 14 A A A 231 5.4 60 3 45
27 52 F A A A A A 5300 20 A A A 221 4.9 59 2.9 150
28 40 F P P A A A 4100 4 A A A 111 5.9 98 3 35
29 55 M P P A A A 6000 8 A A A 30 6 20 1.5 20
30 33 M P P A A A 16700 32 A A A 264 7 59 5.7 456
31 22 M P P A P A 13900 32 P P A 254 5.8 67 5 342
32 56 M P P A P A 28000 56 P P A 321 7.1 70 6 432
33 45 M P P A P A 19800 28 P P A 231 7 68 5.8 200
34 35 M A A A P A 20200 32 A A A 150 6 50 5.4 320
35 37 M A A A P P 4300 40 A A A 189 5.8 27 4.6 278
36 39 M A A A A A 5400 8 A A A 48 6 89 2 23
37 56 M A A A A P 9800 40 A A A 189 4.9 50 3.9 78
38 47 F P P P A P 10000 12 A A A 210 5.1 86 3 290
39 58 F A A A A P 9900 12 A A A 156 4 47 3.6 129
40 54 M A A A A A 10500 20 A A A 187 5.5 60 3.8 156
41 54 M A A A A A 11000 22 A A A 234 5.1 70 3.9 120
42 26 M A A A A P 9600 14 A A A 120 3.9 54 2 256
43 25 F P P A P A 33000 30 A P A 231 6.1 51 4 198
44 28 M P P A P A 18700 33 A P A 253 6.6 57 4.2 200
45 59 M A A A A P 10800 18 A A A 138 4.5 76 3.5 245
46 35 F A A A A P 5500 16 A A A 200 4.2 89 3 342
47 45 M P A A A P 6500 12 A A A 120 5.8 59 3 113
48 46 F A A A P A 7200 80 A A A 110 5.4 60 4 232
49 42 F A A A A A 8400 20 A A A 124 4.1 91 1.3 60
50 60 F P P A P P 4600 12 A A A 174 5.6 50 4 156
M-MALE P-PRESENT TC-TOTAL COUNT SP GM-SPUTUM GRAM STAIN E-EXUDATE
F-FEMALE ABSENT SP CS-SPUTUM CULTURE SENSITIVITY T TRANSUDATE
LOW-LOSS OF WEIGHT
SPUTUM GS-GRAM STAIN
TC-TOTAL  COUNT
S LDH-SERUM LDH
S PROTEIN-SERUM PROTEIN
Pl SUGAR-PLASMA SUGARPLEUR L FLUID LDH
Pl LDH-PLEURAL FLUID LDH
GM-GRAM STAIN
Pl CS-PLEURAL FLUID CULTURE AND SENSITIVITY
Pl-pleural fluid
UL LDH-UPPER LIMIT OF LDH MORE THAN 2/3 RD OF NORMAL SERUM VALUE.
ME-MALIGNANT EFFUSION
PP-PARAPNEUMONIC EFFUSION
TB-TUBERCULOUS EFFUSION
HF-HEART FAILURE
CLD-CHRONIC LIVER DISEASE
Pl GM Pl AFB Pl CS Pl CYTOLOGY UL LDH Protein RATIO LDH RATIO Pl ADA PF CRP NATURE DIAGNOSIS
A A A L P 0.8 2.8181818 60 59.8 E TB
A A A M P 0.533333333 1.44 20 16.2 E ME
P A P P P 0.526315789 1.5625 23 90.7 E PP
A A A N A 0.333333333 0.4255319 17 5 T HF
A A A N P 0.7 1.7325581 54 60.1 E TB
A A A M P 0.533333333 1.6 18 18.9 E ME
P A P P P 0.757142857 2.5 9 96.1 E PP
A A A N A 0.260869565 0.3205128 13 9.1 T HF
A A A N A 0.35 0.4090909 19 12 T HF
A A A L P 0.732142857 1.2608696 43 40.8 E TB
A A A P P 0.877192982 0.5241228 20 150.9 E PP
A A A P P 0.819672131 1.7807018 12 110.7 E PP
P A P P P 0.612244898 1.8680556 14 78.9 E PP
P A P N P 0.714285714 1.2631579 15 85.9 E PP
A A A N A 0.214285714 0.375 18 6.2 T HF
A A A N A 0.15 0.3448276 19 7.4 T CLD
A A A N A 0.317073171 0.4645669 20 4 T CLD
A A A N A 0.344827586 0.3333333 12 8.3 T HF
A P A L P 0.745454545 0.7229437 47 39.9 E TB
A A A P P 0.68852459 1.6419753 28 70.9 E PP
A A A P P 0.877192982 3.1924883 38 102.6 E PP
A A P P P 0.526315789 1.5031447 32 89.7 E PP
P A P N P 0.703125 1.71 40 70.3 E PP
A A A P P 0.620689655 1.5223881 70 70.9 E TB
A P A P P 0.737704918 1.3398693 54 70.2 E TB
A A A P A 0.555555556 0.1948052 42 51.7 E TB
A A A N P 0.591836735 0.678733 48 39.1 E TB
A A A N A 0.508474576 0.3153153 14 4.6 T HF
A A A N A 0.25 0.6666667 17 7.1 T HF
A A A N P 0.814285714 1.7272727 32 55.8 E PP
A A A N P 0.862068966 1.3464567 15 79.7 E PP
A A A P P 0.845070423 1.3457944 13 149.7 E PP
A A A P P 0.828571429 0.8658009 13 143.8 E PP
A A P P P 0.9 2.1333333 39 131.8 E PP
A A A L P 0.793103448 1.4708995 41 40.1 E TB
A A A N A 0.333333333 0.4791667 14 7.6 T HF
A A A L A 0.795918367 0.4126984 52 31.2 E TB
A A A M P 0.588235294 1.3809524 8 19.5 E ME
A A A M P 0.9 0.8269231 7 37.6 E ME
A A A L P 0.690909091 0.8342246 48 56.9 E TB
A A A L P 0.764705882 0.5128205 63 31.4 E TB
A A A M P 0.512820513 2.1333333 20 21.9 E ME
A A A P P 0.655737705 0.8571429 28 90.8 E PP
P A P P P 0.636363636 0.7905138 32 160.7 E PP
A A A L P 0.777777778 1.7753623 44 67.8 E TB
A A A M P 0.714285714 1.71 10 17.8 E ME
A A A M A 0.517241379 0.9416667 17 33.1 E ME
A A A L P 0.740740741 2.1090909 41 70.3 E TB
A A A N A 0.317073171 0.483871 8 8.1 T HF
A A A M P 0.714285714 0.8965517 18 19.6 E ME
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